Oncology CRA
Check the surgery date, collection date, shipping record, and lab receipt against the protocol and lab manual.
Oncology trial operations
In a postoperative colorectal cancer study, a blood draw can depend on the actual resection date and an available tissue specimen. In a metastatic cohort, the dependency may be a qualifying molecular result and prior treatment record.
A postoperative circulating tumor DNA (ctDNA) study may route resection tissue and a later blood sample to the laboratory through different teams. A change to the actual surgery date can change the draw window and the time available for results. The NCI-listed CIRCULATE–North America study is one example of research testing postoperative ctDNA in colon cancer.
Record the actual procedure date and recalculate the collection window using the protocol. Have the CRA reconcile collection, dispatch, receipt, and lab status. Have the CTM track the result deadline against the study milestone and coordinate action with the site and laboratory when the timeline is at risk.
When this handoff needs a sponsor decision, use an executive briefing to clarify who owns it and what evidence will guide the decision.
Request an executive briefing →Check the surgery date, collection date, shipping record, and lab receipt against the protocol and lab manual.
Track pending results against the enrollment or randomization milestone and coordinate site and lab follow-up.
Distinguish late postoperative draws, insufficient tissue, courier exceptions, and lab turnaround before deciding where to intervene.
A Lead CRA can coordinate recurring findings. For scoped SIGNAL Managed Monitoring, a named review lead brings patterns and open actions to the sponsor’s decision owners.